Table 1.
Characteristics of the patients included in the study.
| APS patients (43; 72%) | Suspected APS (17; 28%) | |
|---|---|---|
| ANAGRAPHIC | ||
| Mean age (±S.D.) at data collection | 45.7 (±11.9) | 51.9 (±7.3) |
| Females | 30 (69.8%) | 11 (64.7%) |
| CLINICAL MANIFESTATIONS | ||
| Arterial thrombosis | 21 (48.8%) | 5 (29.4%) |
| Venous thrombosis | 26 (60.5%) | 12 (70.6%) |
| aPL PROFILE AT DIAGNOSIS | ||
| LA (positive, n)* | 37 (86%) | 11 (64.7%) |
| aCL (IgG/M)* | 22 (51.2%) | 7 (41.2%) |
| aβ2GPI (IgG/M)* | 23(53.5%) | 6 (35.3%) |
| ANTICOAGULANT THERAPY AT THE MOMENT OF TESTING | ||
| VKA (warfarin) | 18 (41.9%) | 2 (11.8%) |
| LMWH | 8 (18.6%) | 2 (11.8%) |
| DOAC | 13 (30.2%) | 0 |
| Anti-platelets therapy | 17 (39.5%) | 13 (76.5%) |
SD, Standard Deviation; APS, Antiphospholipid Syndrome; aPL, Antiphospholipid Antibodies; LA, Lupus Anticoagulant; aCL, Anticardiolipin Antibodies; anti-β2GPI, Anti- β2Glycoprotein I antibodies; VKA, Vitamin K antagonists; LMWH, Low Molecular Weight Heparins; DOAC, Direct Anticoagulants.
*
When considering patients with suspected APS: defined as inconsistent LA positivity and/or low levels of ACA IgG/IgM or anti-β2GPI IgG/IgM antibodies 10–30 GPL/MPL.